Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on: December 22,2023 15

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on:December 22,2023 15

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on: December 21,2023 10

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on:December 21,2023 10

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on: December 21,2023 10

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on:December 21,2023 10

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on: December 20,2023 15

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on:December 20,2023 15

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on: October 30,2023 26

What are some recent advancements in proteomics-driven pancreatic oncology research

In a recent narrative review published inProteomes,researchers reviewed the application of proteomics-driven biomarkers for early detection, diagnosis, and treatment of pancreatic cancer.A

Updated on:October 30,2023 26

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023 142

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023 142

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on: October 15,2023 291

Oncolytic Virus Enables the Immune System to Attack Tumors

by Shana SpindlerOne of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identifi

Updated on:October 15,2023 291

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023 87

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023 87

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on: December 17,2023 10

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than

Updated on:December 17,2023 10

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on: December 20,2023 10

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on:December 20,2023 10

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023 25

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023 25

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205